10 Hot Biotech Stocks Under $5 to Buy
On June 4, 2026, CNBC reported that global biopharma M&A is on track for its strongest year since the pre-pandemic peak seven years ago.
Fate Therapeutics Inc (FATE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Redmile Group Jeremy Green | 12,872,946 | $34,756,954 | 2.33% | |
| 2. | AQR Capital Management Cliff Asness | 3,837,229 | $10,360,518 | +28% | 0% |
| 3. | Renaissance Technologies Jim Simons | 2,983,268 | $8,054,824 | +1% | 0.01% |
| 4. | Millennium Management Israel Englander | 2,433,978 | $6,571,741 | 0% | |
| 5. | Citadel Investment Group Ken Griffin | 993,308 | $2,681,931 | +6% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.68 | 397,964 | $668,579.52 | 12,884,277 | 2024-12-20 | Filing | |
| $3.72 | 44,630 | $166,023.60 | 13,180,388 | 2023-12-26 | Filing | |
| $6.18 | 256,639 | $1,586,029.02 | 13,135,758 | 2023-04-21 | Filing | |
| $5.99 | 20,000 | $119,800.00 | 12,879,119 | 2023-04-20 | Filing | |
| $6.00 | 25,700 | $154,200.00 | 12,859,119 | 2023-04-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.46 | 38,800 | $95,405.32 | 589,355 | 2026-08-04 | Filing | |
| $2.46 | 43,947 | $108,100.83 | 591,815 | 2026-08-04 | Filing | |
| $1.88 | 25,590 | $48,083.61 | 628,155 | 2026-05-20 | Filing | |
| $1.88 | 28,946 | $54,482.16 | 635,762 | 2026-05-20 | Filing | |
| $1.06 | 10,589 | $11,275.17 | 387,081 | 2026-01-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,298,895 | $19,707,016 | 0% | |
| 2. | 4,545,893 | $12,273,911 | 0% | |
| 3. | 4,445,536 | $12,002,947 | 0% | |
| 4. | 3,379,064 | $9,123,473 | 1.14% | |
| 5. | 2,049,187 | $5,532,805 | 0% |
News See All
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data
Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc.
10 Best Get Rich Quick Stocks to Buy Now
Everyone’s looking for that one big break, whether in their jobs or the stock market.
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions].
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript
Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate Therapeutics, Inc.
13 Best Booming Stocks to Buy Right Now
Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market turbulence and issuing highly positive outlook for the...
5 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the five most promising cancer stocks according to analysts.
Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript
Operator: Welcome to the Fate Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are mode.
16 Most Shorted Stocks Right Now
One of the most intriguing plays on the stock market is short selling. This is because it goes against conventional investment logic, which typically seeks to profit from an increase in share prices.
Hedge Fund Resource Center